MedTrace Logo

Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers

NCT04066257 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-08-28

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetic interaction between tegoprazan and combination of metronidazole, tetracycline and bismuth in healthy adult volunteers.

Conditions

  • Healthy

Interventions

DRUG

Tegoprazan

Tegoprazan 50 mg tablet

DRUG

Metronidazole

Metronidazole 250 mg tablet

DRUG

Tetracycline

Tetracycline hydrochloride 250 mg capsule

DRUG

Bismuth

Tripotassium bismuth dicitrate 300 mg tablet

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Min-Gul Kim, MD · Chonbuk university hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2019-02-22
Completion
2019-04-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066257 on ClinicalTrials.gov